Drug Delivery Based on Polymeric Materials

Rahul Sinha Department of Zoology, Sant Gadge Baba Amravati University, Dist. Amravati, Maharashtra-444602 Corresponding Author: rahulsinha2710@gmail.com

Abstract

The simultaneous engineering of the core and shell has produced multifunctional polymeric micelles, which combine many functionalities into a single nano-formulation, enabling unlimited control over drug delivery in both space and time. By optimising the size of the nanoparticles, it is possible to increase the accumulation of anticancer medications in the tumourinterstitium. To create a nanocarrier with the lowest possible size is a significant task for current researchers. Although there are other methods used by scientists to increase the accumulation of polymeric micelles loaded with medications in the interstitium of tumours, ligand-mediated technique is regarded as an intelligent drug delivery system. This article provides a quick overview of current advancements in polymeric material-based drug delivery systems.

Keywords: Drug Delivery, Polymeric Materials, Nanomaterials

Introduction

Amphiphile micellar solutions are an efficient method of delivering medications to their targets. Water-insoluble medicines are easily soluble in the hydrophobic environment of the micelle core and loaded for distribution to the necessary sites. Targeted drug delivery systems are created to ensure minimal medication loss and degradation, avoid negative side effects, boost drug bioavailability, and increase drug concentrations in the desired zone of interest. There are several different types of drug carriers that are widely employed, including soluble polymers, insoluble natural and synthetic polymers, microparticles, cells, cell ghosts, lipoproteins, and liposomes based micellar systems. There are benefits and drawbacks to these medication delivery methods [1].

Low molecular weight surfactants are frequently utilised as drug delivery systems, however their micelles are unstable in terms of thermodynamics and kinetics due to high CMC values. Since tumours require low density lipoproteins, lipoproteins are employed to deliver antitumor medications. However, the efficacy of lipoprotein is debatable since drug-incorporated lipoproteins may also be recognised by healthy cells, making them competitors for receptor sites on tumours with natural lipoproteins. The polymeric micelles are regarded as amphiphilic in aqueous systems, with the hydrophobic component eliminated. The versatility of polymeric micelles can be attributed to their distinctive core-shell design, in which the hydrophobic portion creates a place for the encapsulation of hydrophobic medicines, proteins, or DNA via chemical or physical

p-ISSN 2349-9370 / e-ISSN 2582-4848 / Peer Reviewed Annual National Indexed Journal / 98

binding mechanisms.The brush-like topology of the hydrophilic portion of the polymeric micelles makes it possible for the hydrophilic portion to shield the hydrophobic portion from biological invasion. Additionally, the hydrophilic coating reduces the amount of protein that sticks to the micelle. Since polymeric micelles have a size beyond the kidneys' barrier for clearance of nanoparticles (5.5 nm), they have a high drug loading capacity and the potential to transport several medicines over a lengthy period of time. These have an improved permeability and retention effect, which causes them to release nano-carriers in blood and passively accumulate in areas with leaky vasculature. Before they may be exploited as possible drug carriers, wide-ranging polymeric micelles must overcome a number of difficulties [2, 3].

Drug Loading and Release

Chemical conjugation or physical trapping by dialysis are two ways in which the insoluble medicines might be contained in the micellar core. It's possible that there won't be significant drug incorporation from the straightforward equilibration of micelles and drug in water. In the chemical conjugation method, the inclusion of the hydrophobic drug into the polymeric micelle core is caused by the establishment of a covalent connection between the particular group of the drug and the hydrophobic core of the micelles. These linkages hinder steric flow and prevent enzymatic cleavage. The physical approach is better at incorporating drugs than the chemical method. The creation of polyion complex micelles allows for the incorporation of polyionic substances. Drugs are often physically trapped by dialysis or an oil-in-water emulsion process [4].

Engineering of the Micellar Core

Polymeric micelles are designed with the goal of creating formulations that, when administered systemically, might reach therapeutic medication levels. The effectiveness of polymeric micelles for drug loading is significantly influenced by the miscibility between polymers and pharmaceuticals. The degree of hydrophobic interaction between the drug and micellar core determines how much of the medication is encapsulated. The results of molecular simulation studies and empirical evidence point to a significant role for polar interactions and hydrogen bonding between the drug molecules and the micellar core in determining the extent of drug solubilization by polymeric micelles. Drug molecules contain hydrogen-bond forming groups in their structural makeup.

In real life, it has been shown that the type and amount of substituents on the hydrophobic block alter the loading efficiency of particular medications in polymeric micelles. The block copolymers' aggregation number affects how well drugs are loaded. Greater aggregation numbers in micelles indicate higher loading capacities. comparing how different core structural modifications affect polymeric micelles' ability to carry drugs. Polymeric micelles ought to be sturdy enough to allow for the longest possible medication retention in the target area without experiencing any negative side effects up to its evacuation from the body. A micellar system's stability may be understood using kinetic and thermodynamic characteristics [5, 6].

p-ISSN 2349-9370 / e-ISSN 2582-4848 / Peer Reviewed Annual National Indexed Journal / 99

Pharmaceutical Applications

Polymeric micelles and other drug carriers, as well as pharmaceutical applications, both benefit from research into drug targeting mechanisms. The micelles spontaneously penetrate the interstitial through leaky vasculature in the passive drug targeting process. The polymeric micelles' ability to target specific cells and organs while avoiding accumulating in healthy tissues might increase the effectiveness of drugs. The polymeric micelles exhibit prolonged circulation time after intravenous injection because of their tiny size and hydrophilic shell, which reduces the absorption by the monophagocytic system [7].

Due to their large molecular weight, these micelles can also be avoided by renal elimination. Indeed, many hours after intravenous administration, complete polymeric micelles were found in plasma. Nevertheless, liposomes with comparable surface properties appear to circulate for longer than micelles, maybe because extravasations of liposomes from the vasculature are more challenging because of their greater size. Trubetskoy and Torchilin provided an example of how polymeric micelles may enter parts of the body that liposomes have trouble accessing. They demonstrated that polymeric micelles display larger accumulation in the primary lymph node than liposomes do following subcutaneous injection into the rabbit hind paw's dorsum. These micelles also reach the lymph node's systemic circulation [8].

Similar to other drug carriers, the molecular weight and density of the hydrophilic shell affect the plasmatic half-life and absorption of polymeric micelles by the MPS. medicines that are integrated into polymeric micelles may collect inside tumours more than free medicines do, and they may distribute less evenly in non-targeted organs like the heart. Polymeric micelles may build up in malignant tissues as a result of compromised lymphatic drainage and increased vascular permeability [9, 10].

Conclusions

Comparing polymeric micelles to other micellar systems, they are the most effective alternative drug carriers. The integration of significantly larger medication levels, longer blood circulation times, and thermodynamic stability are all benefits of mixed polymeric micelles. The polymeric micelle core has been engineered to have the greatest drug loading capacity and longevity. The ability of polymeric micelles to load drugs is primarily influenced by the length of hydrophobic blocks and the type of substituents present in the core. Chemical conjugation or physical entrapment are two methods that can be used to encapsulate the insoluble medicines in the micellar core. Physical approaches are more advantageous for incorporating drugs than chemical ones. Drugs are often physically trapped by dialysis or oil-in-water emulsification.

Acknowledgements

Authors are very much thankful to Head of Department of Zoology, Sant Gadge Baba Amravati University, Dist. Amravati, Maharashtra – 444602for providing necessary academic help.

p-ISSN 2349-9370 / e-ISSN 2582-4848 / Peer Reviewed Annual National Indexed Journal / 100

References

- [1] M. Yokoyama, Novel passive targetable drug delivery with polymeric micelles, Academic Press, San Diego, 1998, pp. 193.
- [2] M. S. Baboli, G. Favre, P. Canal and G. Soula, Br. J. Cancer, 1993, 68, 319.
- [3] R. A. Firestone, Bioconjugate Chem., 1994, 5, 105.
- [4] R. E. Pagano, A. J. Schroit and D. K. Struck, in Liposomes: From physical structure to therapeutic applications, ed. C. G. Knight, Elsevier, Amsterdam, 1981, pp. 323.
- [5] H. S. Choi, W. Liu, P. Misra, E. Tanaka, J. P. Zimmer, B. I. Ipe, M. G. Bawendi and J. V. Frangion, Nat. Biotechnol., 2007, 25, 1165.
- [6] H. M. Aliabadi and A. Lavasanifar, Expert Opin. Drug Delivery, 2006, 3, 139.
- [7] G. K. Kwon and M. L. Forrest, Drug Dev. Res., 2006, 67, 15.
- [8] K. Kataoka, G. S. Kwon, M. Yokoyama, T. Okano andY. Sakurai, J. Controlled Release, 1993, 24, 119.
- [9] S. Kim, Y. Shi, J. Y. Kim, K. Park and J. X. Cheng, Expert Opin. Drug Delivery, 2010, 7, 49.
- [10] X. B. Xiong, F. Arash, S. M. Garg and A. Lavasanifar, J. Controlled Release, 2011, 155, 248.

资金率